Download PDF
Transfusionsmedizin 2013; 3(4): 185-190
DOI: 10.1055/s-0033-1350837
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Natürliche Killerzellen und Leukämiekontrolle

Natural Killer Cells and the Control of Leukemia
F. Babor
1   Klinik für Kinder-Onkologie, -Hämatologie und Klinische Immunologie, Heinrich-Heine-Universität, Düsseldorf
,
M. Uhrberg
2   Institut für Transplantationsdiagnostik und Zelltherapeutika, Heinrich-Heine-Universität, Düsseldorf
› Author Affiliations
Further Information

Publication History

Publication Date:
20 November 2013 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Natürliche Killer-(NK-)Zellen sind spezialisierte Lymphozyten, die v. a. für die Bekämpfung von Virusinfektionen und Tumorentstehung als „first line of defence“ wichtig sind. Die klinische Relevanz der NK-Zelle im Rahmen der Tumorbekämpfung konnte dabei insbesondere im Bereich der allogenen hämatopoietischen Stammzelltransplantation (HSZT) nachgewiesen werden. So führen Inkompatibilitäten in den HLA-Klasse-I-kodierten Liganden der NK-Zellrezeptoren zwischen Spender und Empfänger zu einer Erkennung myeloischer Leukämien durch NK-Zellen, was sich in einem gesteigerten Graft-versus-Leukemia-(GvL-)Effekt klinisch manifestiert. Die molekulare Basis für diese Beobachtungen sind inhibitorische NK-Zellrezeptoren der KIR-Familie, die nach dem Prinzip der „Missing-Self “-Erkennung durch das Fehlen spezifischer HLA-A-, -B- oder -C-kodierter Liganden zur NK-Zellaktivierung führen. In den letzten Jahren wurden verschiedene genetische Risikokonstellationen der hochpolymorphen KIR und HLA-Klasse-I-Liganden beschrieben, die zu einer verbesserten Auswahl von Fremdspendern führen könnten. In dieser Arbeit wird eine Übersicht über die aktuellen Befunde auf diesem Gebiet gegeben und die Relevanz des KIR-HLA-Klasse-I-Systems für die Entwicklung einer NK-zellbasierten Immuntherapie diskutiert.

Abstract

Natural Killer (NK) cells are specialized lymphocytes that serve important roles in combating viral infections and tumor development as a first line of defense. The clinical relevance of NK cells in the field of tumor surveillance could be clearly shown in the setting of allogeneic stem cell transplantation. Incompatibilities in the HLA class I-encoded ligands of NK cell receptors between donor and recipient lead to recognition of leukemia by alloreactive NK cells, which clinically translates into increased graft-versus-leukemia (GvL) effects. The molecular basis of these observations are inhibitory NK cell receptors of the KIR family, which lead to NK cell activation via „missing self“ recognition triggered by the absence of cognate HLA-A, -B, or -C encoded ligands. In recent years, genetic risk constellations could be defined for the highly polymorphic KIR genes as well as for combinations of KIR genes and their HLA class I ligands, which have the potential to improve stem cell donor selection. In this review, an overview is given about recent developments in this field and the potential of exploiting the KIR/HLA class I ligand system for developing novel NK cell-based immunotherapies.

Schlüsselwörter

NK-Zellen - Leukämie - Onkologie - KIR - ALL - AML - Stammzelltransplantation

Key words

NK cells - leukemia - cancer - KIR - ALL - AML - HSCT
 

  • Literatur

  • 1 Algarra I, Collado A, Garrido F. Altered MHC class I antigens in tumors. Int J Clin Lab Res 1997; 27: 95-102
    CrossrefPubMedGoogle Scholar
  • 2 Anfossi N, Andre P, Guia S et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006; 25: 331-342
    CrossrefPubMedGoogle Scholar
  • 3 Becknell B, Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 2005; 86: 209-239
    PubMedGoogle Scholar
  • 4 Biron CA, Nguyen KB, Pien GC et al. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999; 17: 189-220
    CrossrefPubMedGoogle Scholar
  • 5 Bjorklund AT, Schaffer M, Fauriat C et al. NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood 2010; 115: 2686-2694
    CrossrefPubMedGoogle Scholar
  • 6 Braud VM, Allan DS, OʼCallaghan CA et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998; 391: 795-799
    CrossrefPubMedGoogle Scholar
  • 7 Carrington M, Martin MP. The impact of variation at the KIR gene cluster on human disease. Curr Top Microbiol Immunol 2006; 298: 225-257
    PubMedGoogle Scholar
  • 8 Carson WE, Lindemann MJ, Baiocchi R et al. The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood 1995; 85: 3577-3585
    PubMedGoogle Scholar
  • 9 Castriconi R, Dondero A, Corrias MV et al. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res 2004; 64: 9180-9184
    CrossrefPubMedGoogle Scholar
  • 10 Ciccone E, Pende D, Viale O et al. Evidence of a natural killer (NK) cell repertoire for (allo) antigen recognition: definition of five distinct NK-determined allospecificities in humans. J Exp Med 1992; 175: 709-718
    CrossrefPubMedGoogle Scholar
  • 11 Clausen J, Wolf D, Petzer AL et al. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol 2007; 148: 520-528
    CrossrefPubMedGoogle Scholar
  • 12 Colonna M, Spies T, Strominger JL et al. Alloantigen recognition by two human natural killer cell clones is associated with HLA-C or a closely linked gene. Proc Natl Acad Sci U S A 1992; 89: 7983-7985
    CrossrefPubMedGoogle Scholar
  • 13 Cooley S, Trachtenberg E, Bergemann TL et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009; 113: 726-732
    CrossrefPubMedGoogle Scholar
  • 14 Cooley S, Weisdorf DJ, Guethlein LA et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010; 116: 2411-2419
    CrossrefPubMedGoogle Scholar
  • 15 Curti A, Ruggeri L, DʼAddio A et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 2011; 118: 3273-3279
    CrossrefPubMedGoogle Scholar
  • 16 Davies SM, Ruggieri L, Defor T et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002; 100: 3825-3827
    CrossrefPubMedGoogle Scholar
  • 17 Fauriat C, Ivarsson MA, Ljunggren HG et al. Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood 2010; 115: 1166-1174
    CrossrefPubMedGoogle Scholar
  • 18 Federmann B, Bornhauser M, Meisner C et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study. Haematologica 2012; 97: 1523-1531
    CrossrefPubMedGoogle Scholar
  • 19 Fernandez NC, Treiner E, Vance RE et al. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 2005; 105: 4416-4423
    CrossrefPubMedGoogle Scholar
  • 20 Fischer JC, Ottinger H, Ferencik S et al. Relevance of C1 and C2 epitopes for hemopoietic stem cell transplantation: role for sequential acquisition of HLA-C-specific inhibitory killer Ig-like receptor. J Immunol 2007; 178: 3918-3923
    CrossrefPubMedGoogle Scholar
  • 21 Fischer JC, Uhrberg M. Prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 2012; 367: 2054-2055 author reply 2055
    CrossrefPubMedGoogle Scholar
  • 22 Giebel S, Locatelli F, Lamparelli T et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102: 814-819
    CrossrefPubMedGoogle Scholar
  • 23 Handgretinger R. Negative depletion of CD3(+) and TcRαβ(+) T cells. Curr Opin Hematol 2012; 19: 434-439
    CrossrefPubMedGoogle Scholar
  • 24 Hoglund P, Sundback J, Olsson-Alheim MY et al. Host MHC class I gene control of NK-cell specificity in the mouse. Immunol Rev 1997; 155: 11-28
    CrossrefPubMedGoogle Scholar
  • 25 Hsu KC, Gooley T, Malkki M et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2006; 12: 828-836
    CrossrefPubMedGoogle Scholar
  • 26 Hsu KC, Keever-Taylor CA, Wilton A et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005; 105: 4878-4884
    CrossrefPubMedGoogle Scholar
  • 27 Karre K, Ljunggren HG, Piontek G et al. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319: 675-678
    CrossrefPubMedGoogle Scholar
  • 28 Kim S, Poursine-Laurent J, Truscott SM et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005; 436: 709-713
    CrossrefPubMedGoogle Scholar
  • 29 Kim S, Sunwoo JB, Yang L et al. HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci U S A 2008; 105: 3053-3058
    CrossrefPubMedGoogle Scholar
  • 30 Leung W, Iyengar R, Triplett B et al. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 2005; 174: 6540-6545
    PubMedGoogle Scholar
  • 31 Leung W, Iyengar R, Turner V et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004; 172: 644-650
    PubMedGoogle Scholar
  • 32 Miller JS, Cooley S, Parham P et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007; 109: 5058-5061
    CrossrefPubMedGoogle Scholar
  • 33 Miller JS, Soignier Y, Panoskaltsis-Mortari A et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-3057
    CrossrefPubMedGoogle Scholar
  • 34 Passweg JR, Koehl U, Uharek L et al. Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol 2006; 19: 811-824
    CrossrefPubMedGoogle Scholar
  • 35 Raulet DH, Held W, Correa I et al. Specificity, tolerance and developmental regulation of natural killer cells defined by expression of class I-specific Ly49 receptors. Immunol Rev 1997; 155: 41-52
    CrossrefPubMedGoogle Scholar
  • 36 Rubnitz JE, Inaba H, Ribeiro RC et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010; 28: 955-959
    CrossrefPubMedGoogle Scholar
  • 37 Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100
    CrossrefPubMedGoogle Scholar
  • 38 Schonberg K, Fischer JC, Kogler G et al. Neonatal NK-cell repertoires are functionally, but not structurally, biased toward recognition of self HLA class I. Blood 2011; 117: 5152-5156
    CrossrefPubMedGoogle Scholar
  • 39 Schonberg K, Sribar M, Enczmann J et al. Analyses of HLA-C-specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition. Blood 2011; 117: 98-107
    CrossrefPubMedGoogle Scholar
  • 40 Shi J, Tricot G, Szmania S et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 2008; 143: 641-653
    CrossrefPubMedGoogle Scholar
  • 41 Singh SM, Yanagawa H, Hanibuchi M et al. Augmentation by interleukin-18 of MHC-nonrestricted killer activity of human peripheral blood mononuclear cells in response to interleukin-12. Int J Immunopharmacol 2000; 22: 35-43
    CrossrefPubMedGoogle Scholar
  • 42 Soiffer RJ, Weller E, Alyea EP et al. CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol 2001; 19: 1152-1159
    PubMedGoogle Scholar
  • 43 Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci 2012; 33: 35-41
    CrossrefPubMedGoogle Scholar
  • 44 Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-146
    CrossrefPubMedGoogle Scholar
  • 45 Trowsdale J, Barten R, Haude A et al. The genomic context of natural killer receptor extended gene families. Immunol Rev 2001; 181: 20-38
    CrossrefPubMedGoogle Scholar
  • 46 Uhrberg M, Valiante NM, Shum BP et al. Human diversity in killer cell inhibitory receptor genes. Immunity 1997; 7: 753-763
    CrossrefPubMedGoogle Scholar
  • 47 Vago L, Forno B, Sormani MP et al. Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. Blood 2008; 112: 3488-3499
    CrossrefPubMedGoogle Scholar
  • 48 Valiante NM, Uhrberg M, Shilling HG et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 1997; 7: 739-751
    CrossrefPubMedGoogle Scholar
  • 49 Venstrom JM, Pittari G, Gooley TA et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 2012; 367: 805-816
    CrossrefPubMedGoogle Scholar
  • 50 Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 2002; 20: 217-251
    CrossrefPubMedGoogle Scholar
  • 51 Vivier E, Daeron M. Immunoreceptor tyrosine-based inhibition motifs. Immunol Today 1997; 18: 286-291
    PubMedGoogle Scholar
  • 52 Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006; 6: 595-601
    CrossrefPubMedGoogle Scholar
  • 53 Yawata M, Yawata N, Draghi M et al. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 2006; 203: 633-645
    CrossrefPubMedGoogle Scholar
  • 54 Yawata M, Yawata N, Draghi M et al. MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood 2008; 112: 2369-2380
    CrossrefPubMedGoogle Scholar
  • 55 Young HA, Ortaldo J. Cytokines as critical co-stimulatory molecules in modulating the immune response of natural killer cells. Cell Res 2006; 16: 20-24
    CrossrefPubMedGoogle Scholar
  • 56 Yu J, Heller G, Chewning J et al. Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands. J Immunol 2007; 179: 5977-5989
    PubMedGoogle Scholar
  • 57 Yu J, Venstrom JM, Liu XR et al. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation. Blood 2009; 113: 3875-3884
    CrossrefPubMedGoogle Scholar
  • 58 Zhang M, Yao Z, Dubois S et al. Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. Proc Natl Acad Sci U S A 2009; 106: 7513-7518
    CrossrefPubMedGoogle Scholar